348 related articles for article (PubMed ID: 11346069)
1. Newer dopamine agonists in the treatment of restless legs syndrome.
Weimerskirch PR; Ernst ME
Ann Pharmacother; 2001 May; 35(5):627-30. PubMed ID: 11346069
[TBL] [Abstract][Full Text] [Related]
2. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.
Sun Y; van Valkenhoef G; Morel T
Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
4. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
[TBL] [Abstract][Full Text] [Related]
6. The weight of evidence for ropinirole in restless legs syndrome.
Trenkwalder C
Eur J Neurol; 2006 Oct; 13 Suppl 3():21-30. PubMed ID: 16930379
[TBL] [Abstract][Full Text] [Related]
7. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for restless legs syndrome.
Ferini-Strambi L
Expert Opin Pharmacother; 2009 Mar; 10(4):545-54. PubMed ID: 19284359
[TBL] [Abstract][Full Text] [Related]
9. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
10. Ropinirole in the treatment of restless legs syndrome.
Kakar RS; Kushida CA
Expert Rev Neurother; 2005 Jan; 5(1):35-42. PubMed ID: 15853472
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series.
Dostal M; Weber-Schoendorfer C; Sobesky J; Schaefer C
Eur J Neurol; 2013 Sep; 20(9):1241-6. PubMed ID: 23083216
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
Giorgi L; Asgharian A; Hunter B
Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
[TBL] [Abstract][Full Text] [Related]
13. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
Geyer J; Bogan R
Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
15. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan M; Gill S; Samii A
Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
18. Ropinirole treatment for restless legs syndrome.
Bogan RK
Expert Opin Pharmacother; 2008 Mar; 9(4):611-23. PubMed ID: 18312162
[TBL] [Abstract][Full Text] [Related]
19. Ropinirole: new indication. Restless legs: disproportionate adverse effects.
Prescrire Int; 2006 Oct; 15(85):173-6. PubMed ID: 17128523
[TBL] [Abstract][Full Text] [Related]
20. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
Bayard S; Langenier MC; Dauvilliers Y
Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
